⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VIR News
Vir Biotechnology, Inc. Common Stock
Vir Biotechnology to Participate in the Morgan Stanley 24 th Annual Global Healthcare Conference
businesswire.com
VIR
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
prnewswire.com
VIR
New Jersey Legionella Law Creates Two Compliance Deadlines for Covered Buildings and Facilities
accessnewswire.com
ACGL
AMZN
CHTR
PLD
CCI
EQIX
IBM
GOOGL
MSFT
AMAT
NVDA
INTC
AMD
MU
SMCI
PLTR
CRSP
BIIB
REGN
GILD
MRNA
TSLA
NIO
RIVN
XOM
CVX
SHEL
COP
V
MA
JPM
BAC
WFC
GS
MS
DIS
CMCSA
NFLX
META
PEP
KO
MCD
SBUX
WMT
HD
LOW
COST
TGT
MDT
ABBV
PFE
JNJ
BMY
LLY
AZN
NVO
SNY
AMGN
VRTX
GPRO
GOOG
CRM
ADBE
ORCL
SAP
CSCO
QCOM
TXN
ADSK
MELI
BKNG
EXPE
MAR
HLT
IHG
WYNN
LVS
MGM
CCL
RCL
NCLH
AAL
UAL
DAL
LUV
BA
GD
LMT
RTX
NOC
HON
GE
MMM
CAT
DE
BAX
ISRG
ROST
TJX
BBY
BBWI
SIRI
TMUS
VZ
T
QGEN
ILMN
ALGN
EXAS
IDXX
TDOC
ZBRA
PTC
DDOG
PANW
FTNT
CRWD
SNOW
DD
DOW
ECL
WTRG
AWK
XRAY
SYK
EW
TMO
ABT
BSX
BNTX
NVAX
VIR
EDIT
BEAM
CRBU
ARCT
NVCR
ALNY
GPN
PYPL
COIN
MPWR
NXPI
ON
ROKU
WDAY
SNPS
CDNS
MCHP
AEHR
ASML
KLAC
LRCX
ADI
ANET
CTAS
PAYX
ADP
NOW
TEAM
DOCU
ZS
MDB
PSTG
ONTF
VRSK
VRSN
ASO
ULTA
SE
BABA
JD
PDD
NTES
BIDU
IQ
VIPS
XP
BEKE
EDU
RLX
Form 8-K
sec.gov
VIR
Form 8-K
sec.gov
VIR
Vir Biotechnology Announces Chief Financial Officer Transition
businesswire.com
VIR
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
businesswire.com
VIR
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
prnewswire.com
VIR
Form 8-K
sec.gov
VIR
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
businesswire.com
VIR